To target cellular senescence in diabetic kidney disease: the known and the unknown
Clinical Science · 21.08.2024 · 138 (16) · 991-1007
DOI: 10.1042/cs20240717 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Science, online erschienen am 14.08.2024. Verfasst von Yuehan Wei und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, School of Translational Medicine, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Cellular Senescence, Diabetic Nephropathies. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 175 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council (NHMRC).
Abstract (Originalsprache)
Cellular senescence represents a condition of irreversible cell cycle arrest, characterized by heightened senescence-associated beta-galactosidase (SA-β-Gal) activity, senescence-associated secretory phenotype (SASP), and activation of the DNA damage response (DDR). Diabetic kidney disease (DKD) is a significant contributor to end-stage renal disease (ESRD) globally, with ongoing unmet needs in terms of current treatments. The role of senescence in the pathogenesis of DKD has attracted substantial attention with evidence of premature senescence in this condition. The process of cellular senescence in DKD appears to be associated with mitochondrial redox pathways, autophagy, and endoplasmic reticulum (ER) stress. Increasing accumulation of senescent cells in the diabetic kidney not only leads to an impaired capacity for repair of renal injury, but also the secretion of pro-inflammatory and profibrotic cytokines and growth factors causing inflammation and fibrosis. Current treatments for diabetes exhibit varying degrees of renoprotection, potentially via mitigation of senescence in the diabetic kidney. Targeting senescent cell clearance through pharmaceutical interventions could emerge as a promising strategy for preventing and treating DKD. In this paper, we review the current understanding of senescence in DKD and summarize the possible therapeutic interventions relevant to senescence in this field.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Diabetes, School of Translational Medicine, Monash University, Melbourne, Australia.
- Department of Nephrology, Molecular Cell Laboratory for Kidney Disease, Shanghai Peritoneal Dialysis Research Center, Ren Ji Hospital, Uremia Diagnosis and Treatment Center, Shanghai Jiao Tong University School of Medic…
- Department of Nephrology, Laboratory of Diabetic Kidney Disease, Kidney Research Institute, West China Hospital, Sichuan University, Chengdu, China.
ORCID-Profile: Fang Liu, Zhonglin Chai
Förderung
- National Health and Medical Research Council (NHMRC)
Zitieren
APA
Wei, Y., Mou, S., Yang, Q., Liu, F., Cooper, M. E., & Chai, Z. (2024). To target cellular senescence in diabetic kidney disease: the known and the unknown. Clinical Science, 138(16), 991-1007. https://doi.org/10.1042/cs20240717
Vancouver
Wei Y, Mou S, Yang Q, Liu F, Cooper ME, Chai Z. To target cellular senescence in diabetic kidney disease: the known and the unknown. Clinical Science. 2024;138(16):991-1007. doi:10.1042/cs20240717
BibTeX
@article{Wei2024,
author = {Wei, Yuehan and Mou, Shan and Yang, Qing and Liu, Fang and Cooper, Mark E and Chai, Zhonglin},
title = {To target cellular senescence in diabetic kidney disease: the known and the unknown},
journal = {Clinical Science},
year = {2024},
volume = {138},
number = {16},
pages = {991--1007},
doi = {10.1042/cs20240717}
}
EUVIMED